The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Frank X. Leonard net worth and biography

Frank Leonard Biography and Net Worth

Insider of NovoCure

Frank Leonard has served as Novocure’s Chief Development Officer since September 2020. This newly created executive role has responsibility for engineering, product development, business development, and the overall strategic and operational leadership of Novocure’s innovation platforms.

Mr. Leonard joined Novocure in 2010, and most recently served as the Senior Vice President for Corporate Strategy and Health Policy to help prepare the company for the commercial launch of Optune®. In this role, he established Novocure’s health policy and business development groups, and additionally led various finance functions. Prior to joining Novocure, Mr. Leonard was a venture capital investor focused on high-impact medical technologies. Mr. Leonard holds an A.B. from Harvard and an M.A. from the London School of Economics and Political Science.

What is Frank X. Leonard's net worth?: The estimated net worth of Frank X. Leonard is at least $2.86 million as of November 1st, 2024. Mr. Leonard owns 161,236 shares of NovoCure stock worth more than $2,858,714 as of November 23rd. This net worth estimate does not reflect any other assets that Mr. Leonard may own. Learn More about Frank X. Leonard's net worth.
How do I contact Frank X. Leonard?: The corporate mailing address for Mr. Leonard and other NovoCure executives is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. NovoCure can also be reached via phone at 441534756700 and via email at [email protected]. Learn More on Frank X. Leonard's contact information.
Has Frank X. Leonard been buying or selling shares of NovoCure?: Frank X. Leonard has not been actively trading shares of NovoCure within the last three months. Learn More on Frank X. Leonard's trading history.
Who are NovoCure's active insiders?: NovoCure's insider roster includes Michael Ambrogi (COO), Ely Benaim (Insider), Ashley Cordova (CFO), Asaf Danziger (CEO), William Doyle (Executive Chairman), Wilhelmus Groenhuysen (COO), Jeryl Hilleman (Director), Frank Leonard (Insider), Gabriel Leung (Director), Todd Longsworth (General Counsel), Martin Madden (Director), Pritesh Shah (Insider), and Uri Weinberg (Insider). Learn More on NovoCure's active insiders.
Are insiders buying or selling shares of NovoCure?: During the last twelve months, insiders at the medical equipment provider sold shares 10 times. They sold a total of 11,141 shares worth more than $188,910.17. The most recent insider tranaction occured on November, 1st when EVP Frank X Leonard sold 598 shares worth more than $9,532.12. Insiders at NovoCure own 6.3% of the company. Learn More about insider trades at NovoCure.
Information on this page was last updated on 11/1/2024.

Frank X. Leonard Insider Trading History at NovoCure

Frank X. Leonard Buying and Selling Activity at NovoCure

NovoCure Company Overview

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Today's Range

Now: $17.73

$17.10

$17.89

50 Day Range

MA: $16.50

$14.54

$18.19

2 Week Range

Now: $17.73

$11.29

$24.74

Volume

657,754 shs

Average Volume

1,279,990 shs

Market Capitalization

$1.92 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.71

Financial Prophecy

From Porter & Company | Ad